PT  - JOURNAL ARTICLE
AU  - Roberto A. Salas Fragomeni
AU  - Tali Amir
AU  - Sara Sheikhbahaei
AU  - Susan C. Harvey
AU  - Mehrbod S. Javadi
AU  - Lilja B. Solnes
AU  - Ana P. Kiess
AU  - Mohamad E. Allaf
AU  - Martin G. Pomper
AU  - Michael A. Gorin
AU  - Steven P. Rowe
TI  - Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
AID  - 10.2967/jnumed.117.203570
DP  - 2018 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 871--877
VI  - 59
IP  - 6
4099  - http://jnm.snmjournals.org/content/59/6/871.short
4100  - http://jnm.snmjournals.org/content/59/6/871.full
SO  - J Nucl Med2018 Jun 01; 59
AB  - Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.